UNIONPAY
29.7.2020 10:02:43 CEST | Business Wire | Press release
UnionPay International, the card payment organisation with the world’s largest cardholder base, today announces a partnership with Glovo, the Barcelona-based on-demand economy technology start-up, which enables UnionPay cardholders to use its app initially in Spain, Portugal, France and Italy.
Founded in 2015, Glovo is an on-demand economy technology start-up that allows local stores to offer their products in the same city through the GLOVO App and supports intermediates in the delivery of such products. It is currently present in 22 countries including Croatia, France, Georgia, Italy, Poland, Portugal, Romania, Serbia, Spain and Ukraine.
This new partnership with Glovo enables UnionPay cardholders to make a wider range of purchases without the need to leave home. To encourage take up of the service while some lockdown measures are still in place, UnionPay customers have been offered free delivery until 15 August in Spain, Portugal and France.
UnionPay acceptance in France, Italy, Portugal and Spain has grown significantly in the last 12 months with a large number of online and offline merchants now accepting UnionPay cards. UnionPay’s cardholder base comprises Chinese ex-pats living and working in Europe, students from Asian countries, as well as a rapidly increasing domestic customer base among European nationals. This is particularly the case in Portugal where last year Millennium bcp became the first European bank to issue UnionPay cards.
Wei Zhihong, UnionPay International’s Market Director and Head of Europe said : “As one of the largest bankcard schemes worldwide, we are committed to providing payment ease for our cardholders. In this difficult time, we are making an extra effort, together with our partners, to offer safer and easier services to support our cardholders in Europe. We are very pleased to have reached a partnership with one of the world’s leading on-demand economy technology start-ups. Glovo is a company which has grown rapidly since its foundation in 2015 and through this new partnership the reach of its app is extended to our cardholders.
“With consumer behaviour changing as a result of COVID-19, more people are staying indoors and making purchases. This new partnership will enable our customers to benefit from Glovo’s platform and service, making purchases and arranging pick-ups without having to leave their own home. We are happy that we have been able to agree a delivery fee free period with Glovo to help keep costs down for cardholders. We look forward to announcing many more similar partnerships in the very near future.”
Sacha Michaud, Co-founder of Glovo said: “We are delighted to have reached a new partnership with UnionPay and hope that it represents the beginning of a long-term relationship which will benefit UnionPay card holders throughout France, Italy, Portugal and Spain. We look forward to working together on further partnerships as we move forward.”
With over 8.4 billion cards accumulatively issued worldwide, UnionPay is the card payment organisation with the world’s largest cardholder base. Its global network extends to 179 countries and regions, covering over 52 million merchants and more than 2.9 million ATMs worldwide.
- Ends -
About UnionPay International
UnionPay International (UPI) is a subsidiary of China UnionPay focused on the growth and support of UnionPay’s global business. In partnership with more than 2300 institutions worldwide, UnionPay
International has enabled card acceptance in 179 countries and regions with issuance in 61 countries and regions. UnionPay International provides high quality, cost effective and secure cross-border payment services to the world’s largest cardholder base and ensures convenient local services to a growing number of global UnionPay cardholders and merchants.
For more information, please visit: www.unionpayintl.com/en
For media enquiries please contact:
Citigate Dewe Rogerson
Oliver Parry/ Brandon Stockwell/ Patrick Evans
unionpay@citigatedewerogerson.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005031/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom